Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact? | Zendy

Thomas Schön | Zendy; Pontus Juréen | Zendy; Erja Chryssanthou | Zendy; Christian G. Giske | Zendy; Gunnar Kahlmeter | Zendy; Sven Hoffner | Zendy; Kristian Ängeby | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact?

Author(s) -

Thomas Schön,

Pontus Juréen,

Erja Chryssanthou,

Christian G. Giske,

Gunnar Kahlmeter,

Sven Hoffner,

Kristian Ängeby

Publication year - 2013

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkt150

Subject(s) - rifabutin , rpob , rifampicin , microbiology and biotechnology , mycobacterium tuberculosis , biology , antibacterial agent , breakpoint , antibiotics , genotype , rifamycin , tuberculosis , genetics , medicine , pathology , gene , clarithromycin , chromosomal translocation

It has long been assumed that some rifampicin-resistant Mycobacterium tuberculosis strains are susceptible to, and thus treatable with, rifabutin. However, clinical breakpoints for susceptibility testing of rifabutin as well as the evidence for a clinical effect of rifabutin in rifampicin-resistant strains remains poorly defined. The objective of this study was to re-evaluate the breakpoint for rifabutin in relation to its MIC wild-type distribution and the presence of mutations in rpoB.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research